Vaccine News and Research

Latest Vaccine News and Research

First responders may not be willing to report for work if disaster is a potentially lethal pandemic

Although first responders willingly put themselves in harm's way during disasters, new research indicates that they may not be as willing- if the disaster is a potentially lethal pandemic.

30 Sep 2010

Discovery suggest a new direction for designing vaccines for rare HIV infection

New discoveries about the immune defenses of rare HIV patients who produce antibodies that prevent infection suggest a novel direction for designing new vaccines. Researchers at Rockefeller University and colleagues have now made two fundamental discoveries about the so called broadly neutralizing anti-HIV antibodies, which effectively keep the virus at bay.

30 Sep 2010

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon™ flu vaccine development.

30 Sep 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Malaria experts focus on RTS, S as Malaria Vaccines for the World Conference begins

Scientists and physicians from around the world gathered in Washington, D.C. on Tuesday for the start of the second Malaria Vaccines for the World Conference, SAPA/News24 reports.

30 Sep 2010

UC Berkeley Extension offers new options for career development in biotechnology

Biotechnology professionals in the Bay Area have three new options for career development from UC Berkeley Extension. The professional programs in Regulatory Affairs, Biopharmaceutical Product and Process Development, and Bioscience Manufacturing and Supply Chain join the education leader's lineup of programs and certificates designed to meet the biotechnology industry's demand for trained professionals.

30 Sep 2010

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent), Merck's vaccine for rotavirus gastroenteritis in infants and children, received the Prix Galien USA 2010 Award for Best Biotechnology Product, Merck announced today.

30 Sep 2010

Precautionary guidelines on flu vaccine safety for allergic children

With the flu season looming and health officials calling for across-the-board immunization, some parents may wonder just how safe the egg-based flu vaccine is for children with allergies. Pretty safe, say pediatricians from Johns Hopkins Children's Center: Even though the flu vaccine contains egg protein, most children with egg and other food allergies can be immunized safely with a few basic precautions.

30 Sep 2010

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

Swine flu no longer a threat to Americans: Report

According to the latest research most Americans are immune to the swine flu virus. Results of the study by the National Institute of Allergy and Infectious Diseases, published in the journal mBio show that around 59 percent of the 310 million U.S. population has developed immunity to H1N1 either from exposure to similar viruses, vaccination, or natural H1N1 infection.

29 Sep 2010

Malaria vaccine close to reality

A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.

29 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Outbreak of whooping cough mirrors challenges in developing world, global health official says

The outbreak of whooping cough in Texas, California, and other states this year underscores the critical importance of widespread vaccination coverage, both locally as well as around the world, said a leading global health official attending conferences on world affairs and immunization in Fort Worth this week.

29 Sep 2010

Malaria vaccine development meeting begins in Washington

Agence France-Presse reports on a malaria vaccine development meeting that kicks off Tuesday in Washington, D.C.One of the stars at the meeting will be the RTS,S malaria vaccine, which has been developed by GlaxoSmithKline and the PATH Malaria Vaccine Initiative, with funding from the Bill & Melinda Gates Foundation, the news service writes.

29 Sep 2010

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010

National Jewish Health's liposome-based vaccine receives US patent

National Jewish Health has received a US patent for a new kind of vaccine, which uses a small lipid bubble to deliver an antigen and DNA adjuvant. Chairman of Pediatrics Erwin Gelfand, MD, and former National Jewish Health Professor of Medicine Steve Dow, PhD, developed the new liposome-based adjuvant.

29 Sep 2010

Pieris enters multi-year collaboration with Sanofi-Aventis and Sanofi Pasteur for Anticalin technology

Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.

29 Sep 2010

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

National survey shows 60% of U.S. adults not familiar with sepsis

Sixty percent of U.S. adults are not familiar with sepsis, despite the fact that more than 200,000 Americans die from it every year, making sepsis one of the leading causes of death in the nation. Lack of awareness is even higher among adults over age 65, who are at greater risk of sepsis, according to a new national survey sponsored by The Feinstein Institute for Medical Research in Manhasset, NY, part of the North Shore–LIJ Health System.

28 Sep 2010

Vaccine News and Research

Latest Vaccine News and Research

First responders may not be willing to report for work if disaster is a potentially lethal pandemic

Discovery suggest a new direction for designing vaccines for rare HIV infection

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Circassia announces advancement in T-cell allergy vaccines development

Malaria experts focus on RTS, S as Malaria Vaccines for the World Conference begins

UC Berkeley Extension offers new options for career development in biotechnology

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

Precautionary guidelines on flu vaccine safety for allergic children

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Swine flu no longer a threat to Americans: Report

Malaria vaccine close to reality

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Outbreak of whooping cough mirrors challenges in developing world, global health official says

Malaria vaccine development meeting begins in Washington

CAP cells produce high virus titers upon influenza strain infection

National Jewish Health's liposome-based vaccine receives US patent

Pieris enters multi-year collaboration with Sanofi-Aventis and Sanofi Pasteur for Anticalin technology

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

National survey shows 60% of U.S. adults not familiar with sepsis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in